Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant gain of 64.84% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 24.12%. Over the past 30 days, the price of RGLS has fallen by 42.57%. And in the last five days, it has surged by 51.80%.
Regulus Therapeutics Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $3.79 on 03/12/24 and the lowest value was $0.76 on 03/20/23.
52-week price history of RGLS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Regulus Therapeutics Inc’s current trading price is -44.33% away from its 52-week high, while its distance from the 52-week low is 177.63%. The stock’s price range during this period has varied between$0.76 and $3.79. The Regulus Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.48 million for the day, a figure considerably lower than their average daily volume of 2.93 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Regulus Therapeutics Inc (RGLS) has experienced a quarterly rise of 54.01% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 42.66M and boasts a workforce of 30 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.39, with a change in price of +0.77. Similarly, Regulus Therapeutics Inc recorded 1,807,847 in trading volume during the last 100 days, posting a change of +57.46%.
RGLS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RGLS stands at 0.14. Similarly, the long-term debt-to-equity ratio is also 0.04.
RGLS Stock Stochastic Average
As of today, Regulus Therapeutics Inc’s raw stochastic average for the last 50 days stands at 38.01%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 31.98%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 40.82% and 39.60%, respectively.
